Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade
Authors' conclusion
Adopting diabetes technology in adults with type 1 diabetes decreased HbA1c and increased the number of people achieving an HbA1c <7.0%, supporting the current international recommendation to offer AID systems to most individuals with type 1 diabetes.
Study context
- Population
- Adults (age ≥18 years) with T1D, single centre, 2014–2021; 52.7% female, 80.0% Non-Hispanic White
- Participants
- 4,174 adults15,903 clinic visits
- Exposure
- Diabetes technology users vs nonusers
- Outcome
- Change in mean clinic HbA1c with diabetes technology use
- Follow-up
- 2014 to 2021
Methodological detailssingle-centre, electronic medical record, mixed models adjusted for age, sex and visit year
- Single-centre
- Electronic medical record
- Mixed models adjusted for age, sex and visit year
Main finding
As reported in the abstract
Mean clinic HbA1c
Diabetes technology use, 2014 to 2021
26.9% to 82.7%
Mean clinic HbA1c, 2014 to 2021
7.7-7.5%
P < 0.001
Adults achieving HbA1c <7.0%, 2014 to 2021
32.3-41.7%
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | HbA1c difference (%) (95% CI) | P value | |
|---|---|---|---|
| HbA1c difference between technology users and nonusers · 2014 | 0.36 (0.26–0.47) | P < 0.001 | |
| HbA1c difference between technology users and nonusers · 2021 | 0.93 (0.80–1.06) | P < 0.001 | |
| −0.500.511.5Difference, % (linear scale) |
CGM and automated insulin delivery (AID) use over time · 2014 to 2021
- Significant increases in CGM and AID use
- P < 0.001 for both
Original publication
Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade. Diabetes Care. Published 17 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →